Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials胰高血糖素样肽-1类似物对非糖尿病肥胖/超重成人的减重作用：一篇对随机对照试验进行的系统评价及meta分析

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities

(2014) Asger Lund et al.   European Journal of Internal Medicine

Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes

(2013) A. Ottney   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression

(2013) M. Katout et al.   AMERICAN JOURNAL OF HYPERTENSION

Comparison of the Hypoglycemic Effect of Acarbose Monotherapy in Patients With Type 2 Diabetes Mellitus Consuming an Eastern or Western Diet: A Systematic Meta-analysis

(2013) Qibo Zhu et al.   CLINICAL THERAPEUTICS

Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes

(2013) S. H. Kim et al.   DIABETES CARE

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications

(2013) S. Madsbad   DIABETES OBESITY & METABOLISM

Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemia—When do the Risks of Diabetes Begin? A Consensus Statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists

(2013) Alan Garber et al.   Endocrine Practice

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin

(2013) Mojca Jensterle Sever et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

(2013) T A Wadden et al.   INTERNATIONAL JOURNAL OF OBESITY

Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS

(2013) L van Bloemendaal et al.   JOURNAL OF ENDOCRINOLOGY

Is there a place for incretin therapies in obesity and prediabetes?

(2013) Jens Juul Holst et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Exenatide as a Novel Weight Loss Modality in Patients Without Diabetes

(2012) Jessica L Moreno et al.   ANNALS OF PHARMACOTHERAPY

Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

(2012) Aaron S Kelly et al.   Cardiovascular Diabetology

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme

(2012) K. Niswender et al.   DIABETES OBESITY & METABOLISM

Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight

(2012) J. Jelsing et al.   DIABETES OBESITY & METABOLISM

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis

(2012) Matteo Monami et al.   Experimental Diabetes Research

Impaired Secretion of Total Glucagon-like Peptide-1 in People with Impaired Fasting Glucose Combined Impaired Glucose Tolerance

(2012) Fang Zhang et al.   International Journal of Medical Sciences

Dysfunctional Adiposity and the Risk of Prediabetes and Type 2 Diabetes in Obese Adults

(2012) Ian J. Neeland et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study

(2012) Leigh Perreault et al.   LANCET

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

(2011) M. A. Nauck et al.   DIABETES

Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes

(2011) J. Dushay et al.   DIABETES CARE

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention

(2011) R. A. DeFronzo et al.   DIABETES CARE

Prediabetes: To treat or not to treat?

(2011) Elisavet Moutzouri et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

Comparative Effects of the Long-Acting GLP-1 Receptor Ligands, Liraglutide and Exendin-4, on Food Intake and Body Weight Suppression in Rats

(2011) Matthew R. Hayes et al.   Obesity

Is the GLP-1 system a viable therapeutic target for weight reduction?

(2011) Jenny Tong et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

(2010) Eric A. Schwartz et al.   ATHEROSCLEROSIS

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

(2010) J. Rosenstock et al.   DIABETES CARE

Liraglutide for weight loss in obese people – Authors' reply

(2010) Arne Astrup et al.   LANCET

What is the best treatment for prediabetes?

(2009) Morali D. Sharma et al.   Current Diabetes Reports

What are the risks and the benefits of current and emerging weight-loss medications?

(2009) Jamie R. Robinson et al.   Current Diabetes Reports

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

(2008) David C. Klonoff et al.   CURRENT MEDICAL RESEARCH AND OPINION

Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome

(2008) Karen Elkind-Hirsch et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM